The US healthcare revolution: How are Bayer, PanGenomic Health, and Pfizer positioned?

Bayer – US Health Secretary poses challenge, pipeline offers rays of hope

The appointment of Robert F. Kennedy Jr. as US Secretary of Health presents Bayer with additional regulatory uncertainty. Kennedy announced that glyphosate would be classified as potentially hazardous to health as part of his "Make America Healthy Again" initiative. Although the EPA regulatory agency continues to rate the herbicide as safe, the planned classification significantly increases political and legal pressure. For Bayer, which is already battling more than 65,000 pending lawsuits and is seeking a resolution by the end of 2026, this poses a significant risk. Withdrawal of the product from the US market remains a real option if regulatory certainty is not achieved.

Parallel to these challenges, positive news from pharmaceutical research offers a glimmer of hope. For example, the Phase 2 CONFIDENCE study demonstrated the efficacy of early combination therapy in diabetic kidney disease. The simultaneous administration of finerenone and an SGLT-2 inhibitor significantly reduced an important kidney damage marker (UACR) after just 14 days, more so than the individual therapies. In addition, the prostate cancer drug darolutamide received a third approval from the FDA for metastatic, hormone-sensitive patients. This is based on the ARANOTE study, which showed a strong reduction in the risk of disease progression or death.

Other projects in Bayer's development pipeline are making progress. The neurokinin inhibitor elinzanetant, a potential treatment for severe hot flashes in breast cancer therapy, showed promising efficacy and tolerability in the Phase 3 OASIS-4 study. An application has been submitted in Japan for approval of the contrast agent gadoquatrane, which requires 60% less gadolinium in MRI scans, which is particularly relevant for frequent scans. In addition, the lung cancer drug sevabertinib received a priority review from the FDA. It targets HER2-mutated tumors and has shown high response rates in previously treated patients. These innovations highlight Bayer's focus on unmet medical needs. The stock climbed after a Goldman Sachs recommendation and currently costs EUR 26.26.

PanGenomic Health – AI-driven healthcare platforms

PanGenomic Health is driving the precision medicine revolution with three AI-based platforms. The NARA app uses genetic data and lifestyle tracking to deliver personalized naturopathic recommendations. Mindleap.com combats stress through adaptive self-help programs and therapist matching via telehealth. The clinical tool MUJN analyzes neurobiomarkers for precise therapy adjustments for neurological conditions. All products combine conventional medicine with evidence-based alternative solutions without going through doctors.

Behind the platforms is the Company's proprietary Nustasis AI platform. Proprietary deep learning models process real-time data from genetic analyses via NARA, symptom diaries from Mindleap, and lab values provided by MUJN. The Company relies on multi-layered security measures to minimize the risks of generative AI: medically validated knowledge databases (including PubMed), diagnostic biomarkers as objective control points, and patented evaluation protocols. This results in personalized treatment plans whose effectiveness is continuously monitored.

The business model combines app subscriptions, e-commerce for herbal supplements, and diagnostic services through MUJN. The expansion from women's health solutions to precision neurological diagnostics and mental resilience opens up new target groups with men interested in performance and longevity. With its direct connection between data collection, AI evaluation, and product delivery, PanGenomic clearly distinguishes itself from pure telehealth providers such as Hims & Hers. The digital health market is expected to grow to over USD 700 billion in North America alone by 2030 and offers long-term scaling potential for personalized solutions. The stock recently broke out to the upside and is currently trading at CAD 0.52.

Pfizer – Caught between conflicting US healthcare policies

The appointment of a declared vaccine critic as US Secretary of Health has triggered regulatory uncertainty. Pfizer shareholders reacted immediately with caution when staff cuts at the FDA and tighter approval requirements were announced. In the future, even COVID-19 booster shots will be tested in placebo studies. This represents a paradigm shift that could delay market launches. Despite the minister's more moderate tone in direct talks, the regulatory environment for vaccine manufacturers remains unpredictable.

Following the expiration of pandemic-related special revenues, Pfizer is consistently focusing on efficiency gains and pipeline innovation. Further cost reductions of USD 500 million are planned for 2025, on top of billions in savings already realized. The focus is on oncology and metabolic diseases, where promising cancer therapies are showing clinical success. However, the discontinuation of the Danuglipron obesity project marks a significant setback in the race for oral therapies against Novo Nordisk and Eli Lilly.

Despite an 8% decline in revenue in the first quarter, Pfizer's operational robustness remains impressive. The profit margin remains stable at over 38%. The dividend yield of around 7% is supported by strong cash flows. In the long term, however, patent expiries for high-revenue drugs such as Eliquis are looming by 2030. The acquisition of Seagen is intended to counteract this with antibody technologies, while strict debt reduction is easing the balance sheet. For investors, the question remains whether pipeline innovations can compensate for the expected revenue losses. A share currently costs USD 23.44.

The radical US healthcare reform under Kennedy Jr. is creating a volatile field with clear winners and losers. Bayer is struggling with massive regulatory risks due to the impending glyphosate classification, while its innovative pharmaceutical pipeline is providing important counterpoints with successes in kidney research, oncology, and gynaecology. PanGenomic Health is a digital pioneer benefiting directly from the upheaval. Its AI-driven platforms for personalized naturopathy, mental health, and neurodiagnostics cost-effectively address the growing demand for personalized solutions. Despite stable margins and strong dividends, Pfizer is under pressure. The main reasons are vaccine-critical regulation, the severe setback in obesity drugs, and upcoming patent expiries.